Baird Financial Group’s Invesco Biotechnology & Genome ETF PBE Stock Holding History
Bought
Maintained
Sold
Other funds holding PBE
Baird Financial Group's PBE Position: Q3 2026 in Review
Baird Financial Group sold out of Invesco Biotechnology & Genome ETF (PBE) in Q3 2026, closing a stake of 3,000 shares — an estimated $269K sold.
Baird Financial Group first reported a position in PBE in Q2 2015 and held it in 19 quarters. The position peaked at $301K in Q2 2015. 123 funds tracked by Wall St. Rank hold PBE as of Q3 2026.
- Baird Financial Group reported no remaining Invesco Biotechnology & Genome ETF position as of Q3 2026 after selling out during the quarter.
- Baird Financial Group sold 3,000 Invesco Biotechnology & Genome ETF shares in Q3 2026, an estimated $269K.
- Baird Financial Group first reported a position in Invesco Biotechnology & Genome ETF in Q2 2015 and held it in 19 quarters.
- Baird Financial Group's Invesco Biotechnology & Genome ETF position peaked at $301K in Q2 2015.
- 123 funds tracked by Wall St. Rank held Invesco Biotechnology & Genome ETF as of Q3 2026.
Based on Baird Financial Group's 13F filing for Q3 2026, filed 13 Nov 2026.